Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

R3R01 in Alport Syndrome Patients and Primary Steroid-Resistant Focal Segmental Glomerulosclerosis Ended

2024-512964-73-00 Alport Syndrome (AS) and Primary Steroid-Resistent Foca 2023-01-18
A phase II study of linperlisib (YY-20394) in patients with relapsed or refractory peripheral T/NK cell or Cutaneous T Cell lymphoma Ended

2022-501431-16-00 Relapsed or Refractory Peripheral T/NK Cell or Cutaneou 2023-01-17
Dose ranging study of amlitelimab in adult participants with moderate-to-severe asthma Ended

2024-510641-33-00 Asthma 2023-01-17
A trial to compare efficacy and safety of follitropin delta versus placebo (inactive treatment) in the treatment of men with idiopathic infe… Ended

2023-508430-34-00 Idiopathic male infertility (including oligoasthenozoos 2023-01-12
AMIND - AMIloride for the treatment of Nephrogenic Diabetes insipidus for patients with bipolar disorder treated with lithium: a randomized … Ended

2024-515018-42-00 Patients treated with lithium carbonate for a bipolar d 2023-01-11
Treatment with Xeljanz in a population of patients with cutaneous T cell lymphoma Ended

2022-500599-79-00 Mycosis Fungoides 2023-01-10
Phase 2 Study of MORAb-202 in Previously Treated Metastatic NSCLC AC Ended

2023-504112-15-00 Metastatic Non-Small Cell Lung Cancer 2023-01-04
Clinical study to show if Naronapride tablets are safe and efficient for treatment of delayed stomach emptying and to find the optimal dose. Ended

2023-510195-31-00 Idiopathic or Diabetic Gastroparesis 2023-01-03
An Open Label Study to Evaluate A3907 in Adults with Primary Sclerosing Cholangitis (PSC) Ended

2022-500790-14-00 Primary Sclerosing Cholangitis (PSC) 2023-01-02
Dapagliflozin in Pulmonary Arterial Hypertension (DAPAH) Ended

2024-518551-37-00 Chronic thromboembolic pulmonary hypertension 2023-01-01
SENS-401 to Prevent the Ototoxicity induced by Cisplatin in Adult Subjects with a Neoplastic Disease Ended

2024-511713-38-00 Cisplatine induced hearing loss 2022-12-30
An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s dis… Ended

2022-500424-30-00 Parkinson’s disease 2022-12-28
Phase 2b Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis Ended

2024-514975-16-00 Non-infectious, Intermediate-, Posterior- or Pan-uveiti 2022-12-22
A Phase 2, Open-Label, Adaptive, Dose-Ranging Study with Long-Term Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokin… Ended

2023-507328-22-00 Tenosynovial Giant Cell Tumor 2022-12-20
A Phase 2 double-blind, randomized, placebo-controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participant… Ended

2023-509078-45-00 Multiple sclerosis 2022-12-19
Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carci… Ended

2022-502078-17-00 unresectable hepatocellular carcinoma 2022-12-15
A Phase IIa Study to assess Safety, Tolerability, and Pharmacodynamics of AZD4831 in Adult Participants with Non-cirrhotic NASH with Fibrosi… Ended

2022-500594-13-00 "Non-Alcoholic Steatohepatatis (NASH) is the progressiv 2022-12-14
Insulin Resistance and Statin Treatment in Renal Transplant Recipients and Patients with Chronic Kidney Disease Ended

2022-501068-16-00 Insulin resistance 2022-12-14
Phase 2, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as additional therapy … Ended

2024-512621-88-00 Acute Respiratory Distress Syndrome 2022-12-06
Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Effect of EDG-5506 on Biomarkers in Adults with Neuromuscular Disease Ended

2022-500215-39-00 McArdle Disease 2022-12-06
A study to find out which dose of daridorexant is safe and effective to treat insomnia in children and adolescents 10 to <18 years old Ended

2024-513885-20-00 Insomnia Disorder 2022-12-05
A Phase 2, Randomized, Open-Label, 24-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Dose… Ended

2024-513119-29-00 PMM2-CDG 2022-12-02
Clinical study to investigate the efficacy of botensilimab (AGEN1181) in patients with advanced melanoma refractory to prior checkpoint inhi… Ended

2022-500652-37-00 Advanced melanoma refractory to prior checkpoint inhibi 2022-12-01
MORPHINE PHARMACOKINETICS AND –DYNAMICS IN HEALTHY VOLUNTEERS AND PATIENTS WITH OBESITY AND OBSTRUCTIVE SLEEP APNOEA. AN INVESTIGATOR INITI… Ended

2022-500779-29-00 Obesity and Obstructive Sleep apnoea 2022-12-01